Recipharm extends high-potency oral solid dose services to GMP pilot scale
Company / institutional announcement · Recipharm
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Recipharm has extended high-potency oral solid dose manufacturing at Leganés, Spain, to GMP pilot scale. A contained suite combines dry granulation, tableting, and coating for compounds up to OEB 5. The same pilot equipment can support clinical and small commercial batches, with larger programs transferring to commercial lines at the same site rather than another facility.
Why it may matter
Smaller high-containment batches may reduce transfer complexity, but sponsors still need product-specific evidence of process suitability and scale-up comparability.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections